Survival Benefit From mAb Combo in Select Metastatic CRC Patients

A preplanned analysis of ctDNA found that a subpopulation of mCRC patients with acquired anti-EGFR resistance were sensitive to treatment with Sym004.

Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer Immuno Oncology News Source Type: news